Abstract:Background Randomized clinical trials (RCTs) might not be representative of the real‐world population because of unreasonable exclusion criteria. We sought to determine which groups of patients are excluded from RCTs that included lipid‐lowering therapy. Methods and Results We retrieved all trials from the Cholesterol Treatment Trialists Collaboration and systematically searched for large (≥1000 participants) lipid‐lowering therapy RCTs, defined as statins, ezetimibe, and PCSK9 inhibitors. We predefined groups: older adults (>70 or >75 years), women, non‐Whites, chronic kidney failure, heart failure, immunosuppression, cancer, dementia, treated thyroid disease, chronic obstructive pulmonary disease, mental illness, atrial fibrillation, multimorbidity (≥2 chronic diseases), and polypharmacy. We counted the number of RCTs excluding patients of the predefined groups and meta‐analyzed the prevalence of included patients to obtain pooled estimates with a random‐effects model. We included 42 RCTs (298 605 patients). Eighty‐one percent of trials excluded patients with severe and 76% those with moderate kidney failure. Seventy‐one percent of trials excluded groups of women, 64% excluded patients with moderate to severe heart failure, 64% those with immunosuppressant conditions, 48% those with cancer, 29% those with dementia, and 29% of trials excluded older adults. The pooled prevalence for patients >70 years of age was 25% (95% CI, 0%–49%), 11% (3%–18%) for >75 years of age, and 51% (38%–63%) for multimorbidity. Conclusions The majority of lipid‐lowering therapy trials excluded patients with common diseases, such as moderate‐to‐severe kidney disease or heart failure or with immunosuppression. Underrepresenting certain populations, including women and older adults, might lead to limited transportability of study results and uncertainty on possible side‐effects and efficacy in these groups. Future trials should promote diversity in the recruitment strategies and improve equity in cardiovascular research. Registration URL: ClinicalTrials.gov; Unique Identifier: CRD42021253909. Nonstandard Abbreviations and Acronyms CTTC Cholesterol Treatment Trialists Collaboration LLT lipid‐lowering therapy Clinical Perspective What Is New? Patients with conditions such as severe renal dysfunction (creatinine clearance <30 mL/min), severe congestive heart failure, immunosuppressant conditions, dementia, and mental illness were often excluded in large lipid‐lowering therapy trials, while more than two‐thirds of all studies excluded groups of women. One‐third of the trials excluded patients >75 years of age, with a pooled prevalence of elderly patients (>75 years of age) of only 11%, while no trial, even recent trials, listed multimorbidity or polypharmacy as exclusion or inclusion criterion, with a pooled prevalence of multimorbid patients (defined as ≥2 chronic diseases) of 51% (95% CI, 38%–63%), suggesting that we need more trials that specifically target these populations. What Are the Clinical Implications? Most lipid‐lowering trials excluded large groups of patients managed in clinical practice, which could possibly lead to uncertainty in treating these groups, while exclusion of groups of women may contribute to limited knowledge of the efficacy and safety of lipid‐lowering therapy in women compared with men. Mortality from cardiovascular disease (CVD) is high, causing 8.9 million deaths worldwide by 2019, 1 ≈45% of all deaths in Europe and 16% globally. 2 Primary and secondary CVD prevention measures, such as lifestyle changes or treatment with lipid‐lowering medication, can reduce CVD mortality. Guidelines widely recommend statins as secondary prevention. 3 However, their benefits and harms are less clear for primary prevention, because the net benefit of statins on absolute risk reduction depends on the individual's baseline risk of CVD, 3 , 4 , 5 and their use is more controversial. 6 Evidence of the effects of statins on CVD risk might have been drawn from trials with selected patient groups that do not represent real‐world demographics, as previously observed in RCTs in oth -Abstract Truncated-

Lipid management across Europe in the real-world setting: a rapid evidence review

[Real-World Efficacy of Current Lipid-Lowering Strategies in Patients with Acute Coronary Syndrome. Time to Change the Paradigm for Treatment].

Real-world efficacy of current strategies for lowering LDL cholesterol after acute coronary syndrome. Changing the treatment paradigm

Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis

Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database

The difference between guideline based lipid optimisation and real-world practice in a very high risk population

Lipid-lowering therapy after acute coronary syndromes: a multinational European survey

Management of children with heterozygous familial hypercholesterolemia worldwide: a meta-analysis

Evaluating the Efficacy of a Pre-Established Lipid-Lowering Algorithm in Managing Hypercholesterolemia in Patients at Very High Cardiovascular Risk

Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges

Characterization and LDL-C management in a cohort of high and very high cardiovascular risk patients: The PORTRAIT-DYS study

Lipid-Lowering Therapy after Acute Coronary Syndrome

Lipid‐Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta‐Analysis of Exclusion Criteria

A New Era of Dyslipidemia Management

Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)

Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary

Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table

Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook